Angela Zhou

Manager of Scientific Analysis and Insights, CAS

Bio

Angela Zhou serves as the Executive Editor of CAS Insights and the Lead Scientist in Life Sciences at CAS. Dr. Zhou earned her Ph.D. in Molecular Pharmacology and Toxicology from the University of Southern California, followed by postdoctoral training in cell biology at Johns Hopkins School of Medicine and specialized research in cancer therapeutics at Harvard Medical School.

Prior to joining CAS, Dr. Zhou held faculty positions at Missouri State University and Denison University, concentrating on teaching and research of cancer biology, cell signaling and biochemistry. At CAS, she leads a multidisciplinary team of research and data scientists who leverage comprehensive scientific databases. Dr. Zhou's unique blend of scientific expertise and data analytics leadership enables her team to deliver strategic intelligence, helping organizations navigate emerging trends and opportunities across chemistry, life sciences, and materials science.

Biotechnology

Extremophiles: Unlocking biomedical and industrial innovations from life at the edge

Extremophiles are microorganisms that survive in Earth’s harshest environments. Find out how their unique capabilities are changing biomedicine, environmental clean-ups, and more.
|Informe de percepciones
Biotechnology

Molecular de-extinction opens possibilities for new antibiotics

Molecular de-extinction revives genes and proteins from ancient sources, and it may hold the key to new antibiotics that fight drug-resistant pathogens.
|Article
Ciencia emergente

El futuro de la administración de fármacos basada en lípidos

Resumen del seminario web sobre el panorama de la administración de fármacos basada en lípidos
|ウェビナー
Ciencia emergente

Friend, not foe: Harnessing the gut microbiome for health benefits

The gut microbiome is a complex ecosystem of trillions of bacteria that live in our digestive tracts with health benefits like immunity, improved mental health, and therapeutic options.
|Article
Drug Discovery

ACE2: Targeting a potentially important receptor in disease pathogenesis

The ACE2 protein is the critical target for COVID-19 and other viral infections, and this knowledge has led to new therapeutics.
|Article
Ciencia emergente

Are psychedelics next to treat depression and PTSD?

Recent clinical trials show that psychedelics, when properly controlled, could be used to treat PTSD and other mental health disorders. Learn more.
|Article